Oral Paricalcitol

Authors: Deeks, Emma D.; Lyseng-Williamson, Katherine A.

Source: Treatments in Endocrinology, Volume 5, Number 5, 2006 , pp. 319-325(7)

Buy & download fulltext article:

Price: $57.95 plus tax (Refund Policy)

Abstract:

▴ An oral formulation of paricalcitol has been developed for the prevention and treatment of secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease.

▴ Paricalcitol is a synthetic vitamin D analog that binds to the vitamin D receptor inducing suppression of parathyroid hormone (PTH) secretion.

▴ Oral paricalcitol was significantly more effective than placebo in treating secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease. In a pooled analysis of three well designed, 24-week trials, two consecutive reductions from baseline in intact PTH levels of ≥30% were achieved by significantly more paricalcitol than placebo recipients (91% vs 13%).

▴ In addition, mean levels of the biochemical bone markers serum bone-specific alkaline phosphatase, serum osteocalcin, and urinary pyridinoline were reduced from baseline to a significantly greater extent with paricalcitol than with placebo, indicating a reduction in bone turnover.

▴ Oral paricalcitol was well tolerated; there was no significant difference between paricalcitol and placebo recipients in the incidence of hypercalcemia, hyperphosphatemia, or elevated calcium-phosphorus product.

Keywords: Adis Drug Profiles; Hyperparathyroidism; Kidney disorders; Oral; Paricalcitol; Paricalcitol; Paricalcitol; Paricalcitol

Document Type: Research article

Affiliations: 1: Adis International Inc., Yardley, Pennsylvania, USA

Publication date: 2006-01-01